Impact Biomedical (IBO) Price to Earnings (2024 - 2026)

Impact Biomedical (IBO) has reported Price to Earnings for 3 consecutive years, with 70.85 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 12738.76% year-over-year to 70.85; the trailing twelve-month figure through Jun 2026 stood at 2.64 (down 1181.05% YoY), and the FY2024 full-year result was 0.67, changed N/A from the prior year.
• Price to Earnings retreated to 70.85 in Q2 2026 per IBO's latest filing, from 28.32 in the prior quarter.
• Across five years, Price to Earnings topped out at 5.42 in Q3 2024 and bottomed at 70.85 in Q2 2026.
• Historically, Price to Earnings has averaged 15.53 across 3 years, with a median of 5.54 in 2025.
• The sharpest annual moves came in 2025 and 2026: Price to Earnings tumbled 202.17% in 2025, then sank 12738.76% in 2026.
• Over 3 years, Price to Earnings stood at 0.62 in 2024, then tumbled by 799.24% to 5.54 in 2025, then tumbled by 1180.09% to 70.85 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 70.85, 28.32, and 5.54 for Q2 2026, Q1 2026, and Q3 2025 respectively.